← Back
Data updated: Mar 10, 2026
KING PHARMS LLC
Infectious DiseaseDermatologyOncology
KING PHARMS LLC is a major pharmaceutical company focused on Infectious Disease, Dermatology, Oncology.
1948
Since
25
Drugs
-
Trials
11
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
PENICILLIN G PROCAINE 2025-08-26
Labeling
PENICILLIN G PROCAINE 2025-08-26
Labeling
PENICILLIN G PROCAINE 2025-08-26
Labeling
QUINIDINE SULFATE 2025-08-21
Labeling
QUINIDINE SULFATE 2025-07-29
Labeling
SKELAXIN 2024-06-21
Labeling
TAPAZOLE 2024-06-14
Labeling
PENICILLIN G PROCAINE 2024-06-07
Labeling
PENICILLIN G PROCAINE 2024-06-07
Labeling
PENICILLIN G PROCAINE 2024-06-07
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 25%
2 drugs
Dermatology 25%
2 drugs
Oncology 25%
2 drugs
Metabolic 25%
2 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Baxter specialty
Infectious Disease, Oncology, Dermatology
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease
Discontinued (18)
Company Info
- First Approval
- 1948-04-26
- Latest
- 2025-08-26
- Applications
- 28
FDA Sponsor Names
KING PHARMS LLCKING PHARMS